Canadian Pharmacists Journal最新文献

{"title":"Patient perspectives on the environmental impact of inhalers: A survey in British Columbia","authors":"Darryl Quantz, Gigi Y.C. Wong, Kevin Liang","doi":"10.1177/17151635231202980","DOIUrl":"https://doi.org/10.1177/17151635231202980","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136213753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists provide exceptional patient-centred care (but what if you’re Black?)","authors":"Ross T. Tsuyuki","doi":"10.1177/17151635231204872","DOIUrl":"https://doi.org/10.1177/17151635231204872","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136212351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriateness of proton pump inhibitor therapy in an ambulatory geriatrics clinic: A retrospective cross-sectional analysis","authors":"Ryan Dixon, Jennifer Bolt","doi":"10.1177/17151635231203214","DOIUrl":"https://doi.org/10.1177/17151635231203214","url":null,"abstract":"Background: Proton pump inhibitors are considered potentially inappropriate medications in the geriatric population. The use of proton pump inhibitors by older adults has increased over the past several decades; however, existing literature suggests that only one-third of patients prescribed these medications have a valid indication for use. The aim of this study was to assess the appropriateness of proton pump inhibitor therapy in a population of ambulatory geriatric patients and to determine the impact of an interdisciplinary clinic on their use. Methods: This was a retrospective, cross-sectional study of patients referred to an ambulatory geriatrics clinic between October 2017 and March 2021. Participants were eligible for inclusion if they were taking a proton pump inhibitor at the time of clinic admission. Appropriateness of proton pump inhibitor therapy was assessed based on indication and dosing regimen. Results: In total, 280 participants were included. The mean age was 79.6 years (SD 7.7) and 60% were female. Overall, 94 of 280 (33.6%) participants had a documented valid indication for their proton pump inhibitor. The clinic team intervened to reduce the dose or discontinue 76 of 186 (40.8%) inappropriate proton pump inhibitors. Interpretation: Only one-third of proton pump inhibitors used by ambulatory geriatric patients have a documented appropriate indication for use. Given the medical complexity of this population and their vulnerability to adverse effects, the ambulatory geriatric population should be a priority target for proton pump inhibitor deprescribing initiatives.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136212000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health human resources planning in Canada—Part I: Opportunities and challenges for pharmacy","authors":"Zubin Austin, Natalie Crown","doi":"10.1177/17151635231201802","DOIUrl":"https://doi.org/10.1177/17151635231201802","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135386630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022 Pharmacy Practice Research Abstracts","authors":"PhD Andrea Bishop, PhD Thomas Mahaffey, PhD Todd Boyle, PhD Bobbi Morrison, BSc Danial Khan, BPharmHons Kaitlyn Watson, GradCertAppPharmPrac Fhea Dillon Lee PhD, Yazid Al Hamarneh PharmD","doi":"10.1177/17151635231196198","DOIUrl":"https://doi.org/10.1177/17151635231196198","url":null,"abstract":"To evaluate the impact of the COVID-19 pandemic on the roles of frontline pharmacists and pharmacy services in Canada during the early phase of the pandemic","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"156 1","pages":"S1 - S33"},"PeriodicalIF":1.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49149299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AFPC CPERC 2022 Abstracts: Oral and Poster Presentations.","authors":"","doi":"10.1177/17151635221135415","DOIUrl":"https://doi.org/10.1177/17151635221135415","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 6","pages":"S1-S111"},"PeriodicalIF":1.5,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647401/pdf/10.1177_17151635221135415.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40707280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is community pharmacists' level of comfort and interest in managing patients with or at risk of major neurocognitive disorders?","authors":"Khaarthikaa Murugesu, Olivier Massé, Anne Maheu, Line Guénette","doi":"10.1177/17151635221128552","DOIUrl":"https://doi.org/10.1177/17151635221128552","url":null,"abstract":"Introduction Major neurocognitive disorders (MNCDs) have been forecasted to almost triple globally to 152 million people by 2050. In MNCDs, the brain is impacted so that cognitive processes, such as memory, language, organizational abilities, planning and judgment, gradually deteriorate. With considerable damage, a person’s daily life is impaired, decreasing autonomy and further resulting in requiring assistance with everyday tasks. The Plan Alzheimer du Québec (PAQ) was created in 2013 based on an existing provincial health and social services framework to allow optimal care of patients with cognitive impairments. This initiative equips the Family Medicine Groups (FMGs) of the province to manage patients with cognitive disorders. FMGs are collaborative and interdisciplinary primary care clinics consisting of family physicians, nurses and, more recently, social workers and pharmacists. These professionals provide care and offer resources that aim to sustain the autonomy of patients affected by MNCDs. In line with the PAQ, the Projet GPS is an ongoing pragmatic controlled study funded by the “Fonds de recherche du Québec-Santé.” It aims to measure the impact of pharmacists’ contributions to FMGs regarding patients who either have MNCDs or are undergoing cognitive assessment. FMG pharmacists’ interventions focus on optimizing a patient’s medications. They aim to improve quality of life by managing prescriptions and deprescribing those that are suboptimal. Medication optimization is crucial for older persons to remove medications that may exacerbate their cognitive disorders. Therefore, as a living laboratory-type intervention, the Projet GPS will enable us to explore additional elements of MNCD patients’ journeys, including connecting with community pharmacy. One of a patient’s first contact points with the health care system is the community pharmacy. From a study in 2016, it was seen that about 25% of Canadian seniors typically take 10 or more prescription drugs per year, making community pharmacists an essential player on their health care team. It has been established that the elderly with cognitive problems are more prone to increased risk of adverse drug events. With the notable increase in chronic illnesses within the elderly community, pharmacists are well placed to facilitate the early detection of those who present signs of cognitive impairments and support their health system navigation. Although community pharmacists play a distinct interactive role with patients, which could be advantageous in optimizing the pharmacotherapy of those with or at risk of MNCDs and flagging patients who require medical attention to their FMGs, little is known about their level of comfort and willingness to engage in these activities. Therefore, this project’s goal was to survey pharmacists (both licensed and final-year pharmacy students) practising or wishing to practise in community pharmacy settings about their role among the elderly with or at risk of M","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 6","pages":"302-308"},"PeriodicalIF":1.5,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40479419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and cost-effectiveness of an intensive and abbreviated individualized smoking cessation program delivered by pharmacists: A pragmatic, mixed-method, randomized trial.","authors":"Leslie C E Phillips,&nbsp;Hai Nguyen,&nbsp;Terri L Genge,&nbsp;W Joy Maddigan","doi":"10.1177/17151635221128263","DOIUrl":"https://doi.org/10.1177/17151635221128263","url":null,"abstract":"<p><strong>Background: </strong>Tobacco use is the leading preventable cause of morbidity and mortality in Canada. Smoking cessation programs (SCPs) that are effective, cost-effective and widely available are needed to help smokers quit. Pharmacists are uniquely positioned to provide such services. This study compares the abstinence rates between 2 pharmacist-led SCPs and the cost-effectiveness between these and a comparator group. The study was conducted in St. John's, Newfoundland and Labrador.</p><p><strong>Methods: </strong>This pragmatic, mixed-method trial randomized smokers to either an existing intensive SCP or a new abbreviated SCP designed for community pharmacies. The primary outcome was 6-month abstinence rates. Cost-effectiveness was determined using abstinence rates for the SCPs and a comparator group. Incremental costs per additional quit were calculated for the trial duration, and incremental costs per life-year gained were estimated over a lifetime.</p><p><strong>Results: </strong>Quit rates for the SCPs were 36% (intensive) and 22% (abbreviated) (<i>p</i> = 0.199). Incremental costs per life-year gained for the SCPs were $1576 (intensive) and $1836 (abbreviated). The incremental costs per additional quit, relative to the comparator group, for the SCPs were $1217 (intensive) and $1420 (abbreviated).</p><p><strong>Discussion: </strong>Both SCPs helped smokers quit, and quit rates exceeded those reported for a comparator group that included a general population of adult smokers (~7%). The incremental costs per additional quit for both SCPs compare favourably to those reported for other initiatives such as quit lines and hospital-based interventions.</p><p><strong>Conclusion: </strong>Pharmacist-led smoking cessation programs are effective and highly cost-effective. Widespread implementation, facilitated by remuneration, has potential to lower smoking prevalence and associated costs and harms.</p>","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 6","pages":"334-344"},"PeriodicalIF":1.5,"publicationDate":"2022-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40707278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis.","authors":"Ann Chang,&nbsp;Shanzeh Chaudhry,&nbsp;Daniel McCormack,&nbsp;Tara Gomes,&nbsp;Anisa Shivji,&nbsp;Mina Tadrous","doi":"10.1177/17151635221126481","DOIUrl":"https://doi.org/10.1177/17151635221126481","url":null,"abstract":"<p><strong>Background: </strong>Due to the coronavirus disease 2019 (COVID-19) pandemic, Health Canada issued an exemption to the Controlled Drugs and Substances Act (CDSA) on March 19, 2020, enabling pharmacists to act as prescribers of controlled substances to support continuity of care. Our study investigates utilization of the CDSA exemption by Ontario pharmacists with the intent to inform policy on pharmacist scope of practice and to improve future patient outcomes.</p><p><strong>Methods: </strong>We conducted a time-series analysis of pharmacist-prescribed opioid, benzodiazepine and stimulant claims data using Ontario Narcotics Monitoring System (NMS) data between January 2019 and December 2021. We used ARIMA modelling to measure the change to these classes of claims and to opioid claims containing quantities greater than a 30-day supply.</p><p><strong>Results: </strong>Postexemption, the average weekly number of pharmacist-prescribed opioid, benzodiazepine and stimulant claims rose by 146% (160 to 393 claims/week), 960% (49 to 515 claims/week) and 2150% (8 to 177 claims/week), respectively. There was a 2-week lag period between the time of announcement and the statistically significant increase in claims on April 5, 2020(<i>p</i> < 0.0001). The total number of claims for opioid quantities exceeding a 30-day supply decreased by 60%. Cumulative pharmacist-prescribed claims accounted for under 2% of the total NMS claims.</p><p><strong>Interpretation: </strong>Ontario pharmacists used the CDSA exemption but were prescribing at low rates. These findings suggest an effective change to pharmacy practice as the low rates show pharmacists used the exemption as a last line of defense. This may lead to further studies exploring treatment breaks during the COVID-19 pandemic and future changes to pharmacist scope to benefit patients.</p>","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 6","pages":"326-333"},"PeriodicalIF":1.5,"publicationDate":"2022-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40707279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Taking our best shot: Pharmacy's vaccination success story.","authors":"Sherilyn K D Houle,&nbsp;Nancy M Waite,&nbsp;Ross T Tsuyuki","doi":"10.1177/17151635221128223","DOIUrl":"https://doi.org/10.1177/17151635221128223","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"155 6","pages":"293-295"},"PeriodicalIF":1.5,"publicationDate":"2022-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647397/pdf/10.1177_17151635221128223.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40707274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}